Feb 28, 2023 / 03:00PM GMT
Operator
Greetings and welcome to the Nykode Therapeutics Q4 webcast. (Operator Instructions) Please note, this conference is being recorded. I will now turn the conference over to our host, Michael Engsig, CEO. Thank you. Please begin.
Michael Engsig - Nykode Therapeutics ASA - CEO
Thank you very much, operator. And also from my side, a very warm welcome to all the participants for this quarterly webcast here on our financial results and update on the company highlights.
Just to begin with, a quick look at our forward-looking statements. We assume you are all familiar with those. And on that note, we'll move forward. Together with me, I'm pleased to have Agnete Fredriksen, our Chief Business Officer and Co-founder; as well as Harald Gurvin, our Chief Financial Officer.
A quick introduction to Nykode Therapeutics for those of you who are new to the story. Nykode is a clinical-stage immunotherapy company.
We are entirely focused on exploiting our unique and proprietary immunotherapy platform, which uniquely targets the antigens to the antigen
Q4 2022 Nykode Therapeutics ASA Earnings Call Transcript
Feb 28, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers